Colorectal Cancer (CRC) Clinical Trial
Official title:
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance ("USOPTIVAL")
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Status | Recruiting |
Enrollment | 1300 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 84 Years |
Eligibility | Inclusion Criteria: Arm A: 1. Must be 45-84 years of age. 2. Must have a suspected advanced adenoma or be newly diagnosed with CRC, still not resected, and scheduled for surgery. 3. Able to comprehend, sign, and date the written informed consent document. Arm B: 1. Must be 45-84 years of age. 2. Able and willing to undergo a standard-of-care screening colonoscopy within 60 days. 3. Able to comprehend, sign, and date the written informed consent document. Exclusion Criteria: Arm A Only: 1. Subject with curative biopsy during colonoscopy. Arm B Only: 1. Subjects with positive FIT Test results in the 6 months preceding enrollment. 2. Subject has a current diagnosis of cancer. Arms A & B: 1. Subject has a personal history of aerodigestive or digestive tract cancers. 2. Subjects having undergone previous partial surgical removal of one or more portions of their colon due to a reason other than colorectal cancer. 3. Has a known diagnosis or personal history of any of the following high-risk indications for colorectal cancer: 1. Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease. 2. Familial adenomatous polyposis ("FAP", including attenuated FAP). 3. Hereditary non-polyposis colorectal cancer syndrome ("HNPCC" or "Lynch Syndrome"). 4. Serrated polyposis syndrome 5. 2 first-degree relatives (e.g., parents, siblings, and offspring) who have been diagnosed with colon cancer. 6. One first-degree relative with CRC diagnosed before the age of 60. 4. A significant disease which, in the Investigator's opinion, would exclude the subject from the study. 5. Legal incapacity or limited mental capacity. 6. Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent. 7. The patient has a known or documented previous or current medical history of infectious diseases that can be transmitted through blood (E.g. Hepatitis, HIV, etc.), including patients that have been treated, are currently being treated, or have not been treated for that conditions. 8. The patient is known to be pregnant when recruited or during her participation in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Precision Recearch Institute | Chula Vista | California |
United States | Center for Gastrointestinal Disorders | Hollywood | Florida |
United States | Vilo Research Group | Houston | Texas |
United States | Lakeland Regional Cancer Center | Lakeland | Florida |
United States | Ochsner Clinic | New Orleans | Louisiana |
United States | Mid Hudson Medical Research | New Windsor | New York |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Gastroenterology Consultants of SW Virginia | Roanoke | Virginia |
United States | Medical Associates Research Group | San Diego | California |
United States | Precision Research Institute | San Diego | California |
United States | Springfield Clinic | Springfield | Illinois |
United States | Clinical Trials Network | Union City | Tennessee |
United States | Frontier Clinical Research | Uniontown | Pennsylvania |
United States | Clinical Research of California | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
Universal Diagnostics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing | Samples Collected for Testing | Within 12 months of sample collection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
Completed |
NCT01450319 -
A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
|
Phase 2 | |
Active, not recruiting |
NCT05462717 -
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02903914 -
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03253185 -
A Study of SC-007 in Subjects With Advanced Cancer
|
Phase 1 | |
Completed |
NCT00851045 -
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06026410 -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04622423 -
Advanced Therapies for Liver Metastases
|
||
Active, not recruiting |
NCT02955940 -
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
|
Phase 2 | |
Completed |
NCT02327078 -
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
|
Phase 1/Phase 2 | |
Completed |
NCT03314935 -
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05379985 -
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
|
Phase 1 | |
Recruiting |
NCT05648955 -
Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment
|
Early Phase 1 | |
Completed |
NCT00165854 -
Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05706129 -
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02646748 -
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT02005913 -
A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence
|
N/A | |
Recruiting |
NCT04256707 -
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00483080 -
Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)
|
Phase 2 |